Pharmaceuticals Singapore

Singapore Allogeneic Cell Therapy Market Analysis, 2024–2034

Singapore Allogeneic Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Cell Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Singapore · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.3 Mn Estimated value
Estimate 2025 $1.6 Mn 0.1% of the global market
Projected 2034 $12.1 Mn 666.8% Adds $10.5 Mn over 9 forecast years
CAGR 2025–2034 25.4% Faster than 92% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Singapore is 0.11% of the global market.
  • In APAC, the largest is China at $102.7 Mn.
  • Fastest growing: India at 28% a year.
  • Singapore ranks 10th of 10 by size in APAC.

Market size projection

Singapore

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$10.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Allogeneic Cell Therapy Market market size by year, Singapore
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.3 Mn — —
2025 (base) $1.6 Mn +$0.3 Mn —
2026 (forecast) $2.0 Mn +$0.4 Mn +25.4%
2027 (forecast) $2.5 Mn +$0.5 Mn +57.3%
2028 (forecast) $3.1 Mn +$0.6 Mn +97.2%
2029 (forecast) $3.9 Mn +$0.8 Mn +147.3%
2030 (forecast) $4.9 Mn +$1.0 Mn +210.1%
2031 (forecast) $6.1 Mn +$1.2 Mn +288.9%
2032 (forecast) $7.7 Mn +$1.6 Mn +387.6%
2033 (forecast) $9.6 Mn +$1.9 Mn +511.5%
2034 (forecast) $12.1 Mn +$2.4 Mn +666.8%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.41 Bn
  2. US $629.0 Mn
  3. North America $596.0 Mn
  4. APAC $329.0 Mn
  5. Europe $238.5 Mn
  6. China $102.7 Mn
  7. Canada $98.3 Mn
  8. Japan $80.4 Mn
  9. Germany $55.9 Mn
  10. Middle East $57.2 Mn
  11. Latin America $56.5 Mn
  12. France $39.7 Mn
  13. Italy $33.5 Mn
  14. UK $30.3 Mn
  15. Spain $30.2 Mn
  16. Brazil $30.7 Mn
  17. India $30.6 Mn
  18. Ecuador $28.9 Mn
  19. Mexico $22.7 Mn
  20. Saudi Arabia $23.0 Mn
  21. Australia $19.3 Mn
  22. Africa $18.9 Mn
  23. New Zealand $16.5 Mn
  24. Russia $13.1 Mn
  25. South Africa $8.3 Mn
  26. UAE $7.8 Mn
  27. Egypt $4.3 Mn
  28. Philippines $3.0 Mn
  29. Hong Kong $2.4 Mn
  30. Malaysia $2.0 Mn
  31. Thailand $1.7 Mn
  32. Singapore (this report) $1.6 Mn
  33. Kenya $1.1 Mn

The Singapore Allogeneic Cell Therapy Market Analysis Executive Summary

Allogeneic cell therapies use cells from healthy donors to make ready-to-use treatments that do not have to be made for each patient.

Key segments of the allogeneic Cell Therapy market include cell type (T Cells, NK Cells and Stem Cells) and indication (Oncology, Autoimmune and Regenerative Medicine).

Singapore Allogeneic Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the allogeneic Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the allogeneic Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the allogeneic Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for Allogeneic Cell Therapy Market in Singapore

The allogeneic Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Allogeneic Cell Therapy Market in Singapore

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allogeneic Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Singapore.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Allogeneic Cell Therapy right now, from free public sources.

Clinical trials

1 active trial in Singapore

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Beijing Biotech 13 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Allogene Therapeutics 4 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Nkarta, Inc. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Poseida Therapeutics, Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  5. RHEACELL GmbH & Co. KG 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 103 papers since 2021 (worldwide)

  1. Antibody‒cell conjugates: A novel "off-the-shelf" modality bridging ADCs and CAR-T for cancer immunotherapy. Acta pharmaceutica Sinica. B, 2026
  2. Immune Evasion Strategies of Human Poxviruses: A Roadmap for Engineering Low-Immunogenic CAR-Based and iPSC-Derived Cell Products. Cells, 2026
  3. HLA-Engineered iPSC-Derived Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Mice. Cells, 2026
  4. Allogeneic Human Bone Marrow-Derived Mesenchymal Stem Cells Accelerate Diabetic Wound Healing via Inflammation Suppression and Angiogenesis Promotion: A Preclinical Study. The Kaohsiung journal of medical sciences, 2026
  5. Genetically engineered hypoimmunogenic iPSCs: Strategies and considerations for clinical applications. Regenerative therapy, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Allogeneic Cell Therapy in context

Singapore compared

  • Health spending per person: 3,922 US$ per person (2023). World: 1,317 US$ per person (2023). 3rd highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.83 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.2% of people (2025). World: 10.4% of people (2025). 7th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Allogeneic Cell Therapy are running in Singapore?
1 study is recruiting, active or about to start in Singapore.[4]
How much research is published on Allogeneic Cell Therapy?
PubMed lists 103 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Allogeneic Cell Therapy in Singapore? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Singapore

See all
Same topic, other categories

Related on cell and gene therapy and biologics and biosimilars

See the topic